Tuesday, March 10, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Fair Isaac Shares: A Market Divided by Extreme Views

Dieter Jaworski by Dieter Jaworski
November 27, 2025
in Analysis, Tech & Software, Trading & Momentum
0
Fair Isaac Stock
0
SHARES
20
VIEWS
Share on FacebookShare on Twitter

Fair Isaac Corporation finds itself at the center of a dramatic market divergence. While technical indicators flash signals of strength, a substantial chasm separates the assessments of financial analysts. Price targets ranging from $1,038 to $2,170 define the current polarized sentiment surrounding the stock.

Institutional and Insider Selling Adds Pressure

Recent activity from major investors provides crucial context for the stock’s volatility. Data reveals that Silphium Asset Management scaled back its stake in Fair Isaac by 25.0%. The firm disposed of 383 shares, leaving it with a holding of 1,152 shares valued at approximately $2.1 million.

This institutional pullback aligns with a pattern of insider disposals. At the beginning of November, CEO William J. Lansing sold 2,400 shares for roughly $4.16 million. In total, over the past 90 days, company insiders have liquidated 20,432 shares with a collective value of about $32.25 million. Such concentrated selling activity is frequently interpreted by the market as a cautionary signal for near-term price appreciation.

A Stark Divide in Analyst Conviction

The contrasting opinions from Wall Street researchers could scarcely be more pronounced. On November 26, Autonomous Research demonstrated a bearish stance by reducing its price target to $1,038 and reaffirming its “Underperform” recommendation. This rating suggests the firm anticipates significant downward movement from the current trading level.

In a sharp rebuttal to this pessimistic outlook, RBC Capital maintained a decidedly bullish position on the very same day. Analyst Ashish Sabadra confirmed a “Buy” rating, supporting it with a lofty price objective of $2,170. The gap of over $1,100 between these two prominent assessments underscores the profound uncertainty in determining the stock’s fair value.

Should investors sell immediately? Or is it worth buying Fair Isaac?

Key Data Points:
* Bearish Price Target: Autonomous Research at $1,038
* Bullish Price Target: RBC Capital at $2,170
* Institutional Selling: Silphium cuts holding by 25%
* Technical Strength: Relative Strength Rating improved from 63 to 74
* Valuation: Lofty P/E ratio of 67.7

Technical Resilience Meets Lofty Valuation

Despite the skepticism from certain analysts and the wave of selling, the stock exhibits notable technical vigor. Its Relative Strength Rating, a metric that gauges price performance against the broader market, advanced on Wednesday from 63 to 74. This improvement indicates building momentum relative to the overall market over the preceding 52-week period.

From a fundamental perspective, the company’s elevated valuation remains the core point of contention. With a market capitalization of $42.6 billion and a price-to-earnings ratio exceeding 67, Fair Isaac’s stock appears to be pricing in flawless execution. The firm recently posted quarterly revenue of $515.8 million and adjusted earnings per share of $7.74. While these figures confirm ongoing growth, the “Underperform” rating from Autonomous Research implies that the current valuation multiples may be unsustainable.

The question for investors is whether the shares can bridge this extreme valuation gap. The tension between the confirmed 2026 EPS forecast of $38.17 and the present high multiples is a primary driver of volatility. Market participants are currently balancing the stock’s improved technical momentum against the tangible selling pressure from corporate insiders and institutional funds.

Ad

Fair Isaac Stock: Buy or Sell?! New Fair Isaac Analysis from March 10 delivers the answer:

The latest Fair Isaac figures speak for themselves: Urgent action needed for Fair Isaac investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 10.

Fair Isaac: Buy or sell? Read more here...

Tags: Fair Isaac
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Wolters Kluwer Stock
AI & Quantum Computing

Wolters Kluwer’s AI Healthcare Ambitions Take Center Stage at HIMSS 2026

March 10, 2026
Axa Stock
Analysis

AXA Strengthens Energy Insurance Leadership Amid Sector Boom

March 10, 2026
Unicredit Stock
Analysis

UniCredit’s Operational Resilience Stands Out in a Fragmented European Market

March 10, 2026
Next Post
Lear Stock

Lear Shares: Institutional Buying Surge Meets Cautious Market Sentiment

Travelers Stock

Insider Selling at Travelers Raises Eyebrows Among Investors

AMN Healthcare Services Stock

AMN Healthcare Stock: A Battlefield for Bulls and Bears

Recommended

Tech-Innovations

Analysts Remain Bullish on Zscaler with Revised Price Targets

2 years ago
Uber Stock

Uber Faces Danish Antitrust Probe in Setback to European Expansion

6 months ago
Assembly Biosciences Stock

Assembly Biosciences Shares Maintain Strong Upward Momentum

4 months ago
Redcare Pharmacy Stock

Redcare Pharmacy Shares Plunge Amidst Growth Paradox

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

UniCredit’s Operational Resilience Stands Out in a Fragmented European Market

Partners Group Reports Robust 2025 Results Amid Share Price Weakness

Zurich Insurance Strengthens European Footprint with Irish Acquisition

Henkel’s Strategic Pivot: A Key Acquisition Ahead of Earnings

First Majestic Silver’s Stock Volatility Mirrors Underlying Metal Prices

A Pivotal Week for RTL Group: Financial Results and Regulatory Scrutiny Converge

Trending

UBS Stock
Banking & Insurance

UBS Faces Regulatory Crossroads Amid Record Profits

by SiterGedge
March 10, 2026
0

UBS Group AG concluded its latest fiscal year with a powerful financial performance, yet finds its future...

Wolters Kluwer Stock

Wolters Kluwer’s AI Healthcare Ambitions Take Center Stage at HIMSS 2026

March 10, 2026
Axa Stock

AXA Strengthens Energy Insurance Leadership Amid Sector Boom

March 10, 2026
Unicredit Stock

UniCredit’s Operational Resilience Stands Out in a Fragmented European Market

March 10, 2026
Partners Group Stock

Partners Group Reports Robust 2025 Results Amid Share Price Weakness

March 10, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • UBS Faces Regulatory Crossroads Amid Record Profits
  • Wolters Kluwer’s AI Healthcare Ambitions Take Center Stage at HIMSS 2026
  • AXA Strengthens Energy Insurance Leadership Amid Sector Boom

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com